Moderna Inc. reported that its Omicron-adapted vaccines produced a better immune response against the BA.4/5 subvariants in a mid- to late-stage study, when given as a booster dose, compared to its parent vaccine. This was announced by the company on November 14.
The data shows that Moderna’s two Omicron-adapted shots, mRNA-1273.214 and mRNA-1273.222, produced a greater antibody response against the BA.4/5 subvariants than its original shot in vaccinated and boosted adults, the company said. whose statement was cited by the Reuters agency.
Moderna, however, said neutralizing antibody response levels were reduced nearly 5-fold against the emerging subvariant BQ.1.1 compared to BA.4/5, in an analysis of about 40 participants, although the neutralizing activity of the virus still remained "robust."
For its part, the company Pfizer Inc and its German partner, BioNTech, which also produce COVID vaccines with the messenger RNA platform, had said earlier this month that their injection adapted to Ómicron aimed at the BA.4/5 subvariants had produced a strong antibody response in older adults compared to the original injection after one month.
Based on data from preclinical studies, Omicron-adapted injections manufactured by Moderna and Pfizer have already been approved in the US in both adults and children 5 years and older.
According to government data, nearly 31.4 million Americans received the update as of Nov. 9, and about 5.1 million were vaccinated last week.
